A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors ; volume:9 ; number:1 ; day:17 ; month:1 ; year:2019 ; pages:1-16 ; date:12.2019
Scientific reports ; 9, Heft 1 (17.1.2019), 1-16, 12.2019
- Classification
-
Naturwissenschaften
- Creator
-
Menon, Malini
Elliott, Richard
Bowers, Leandra
Balan, Nicolae
Rafiq, Rumana
Costa-Cabral, Sara
Munkonge, Felix
Trinidade, Ines
Porter, Roderick
Campbell, Andrew D.
Johnson, Emma R.
Esdar, Christina
Buchstaller, Hans-Peter
Leuthner, Birgitta
Rohdich, Felix
Schneider, Richard
Sansom, Owen
Wienke, Dirk
Ashworth, Alan
Lord, Christopher J.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-018-36447-4
- URN
-
urn:nbn:de:101:1-2019021317101936941176
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:47 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Menon, Malini
- Elliott, Richard
- Bowers, Leandra
- Balan, Nicolae
- Rafiq, Rumana
- Costa-Cabral, Sara
- Munkonge, Felix
- Trinidade, Ines
- Porter, Roderick
- Campbell, Andrew D.
- Johnson, Emma R.
- Esdar, Christina
- Buchstaller, Hans-Peter
- Leuthner, Birgitta
- Rohdich, Felix
- Schneider, Richard
- Sansom, Owen
- Wienke, Dirk
- Ashworth, Alan
- Lord, Christopher J.
- SpringerLink (Online service)
Other Objects (12)
CDK4/6 inhibitors: a novel strategy for tumor radiosensitization
Hämatologische Toxizitäten von CDK4/6 Inhibitoren
Targeting CBX3 with a Dual BET/PLK1 Inhibitor Enhances the Antitumor Efficacy of CDK4/6 Inhibitors in Prostate Cancer
Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer
Brustkrebstherapie mit CDK4/6-Inhibitoren: Gemeinsamkeiten und Unterschiede
Position paper on CDK4/6 inhibitors in early breast cancer
Recent progress of CDK4/6 inhibitors’ current practice in breast cancer
MYC induces CDK4/6 inhibitors resistance by promoting pRB1 degradation
CDK4/6 inhibitor palbociclib suppresses IgE-mediated mast cell activation
Recent advances of highly selective CDK4/6 inhibitors in breast cancer
Identification of potential novel drivers and biomarkers of CDK4/6 inhibitor resistance in metastatic breast cancer
Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer
CDK4/6 inhibitors: a novel strategy for tumor radiosensitization
Hämatologische Toxizitäten von CDK4/6 Inhibitoren
Targeting CBX3 with a Dual BET/PLK1 Inhibitor Enhances the Antitumor Efficacy of CDK4/6 Inhibitors in Prostate Cancer
Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer
Brustkrebstherapie mit CDK4/6-Inhibitoren: Gemeinsamkeiten und Unterschiede
Position paper on CDK4/6 inhibitors in early breast cancer
Recent progress of CDK4/6 inhibitors’ current practice in breast cancer
MYC induces CDK4/6 inhibitors resistance by promoting pRB1 degradation
CDK4/6 inhibitor palbociclib suppresses IgE-mediated mast cell activation
Recent advances of highly selective CDK4/6 inhibitors in breast cancer
Identification of potential novel drivers and biomarkers of CDK4/6 inhibitor resistance in metastatic breast cancer
Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer
CDK4/6 inhibitors: a novel strategy for tumor radiosensitization
Hämatologische Toxizitäten von CDK4/6 Inhibitoren
Targeting CBX3 with a Dual BET/PLK1 Inhibitor Enhances the Antitumor Efficacy of CDK4/6 Inhibitors in Prostate Cancer
Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer
Brustkrebstherapie mit CDK4/6-Inhibitoren: Gemeinsamkeiten und Unterschiede
Position paper on CDK4/6 inhibitors in early breast cancer
Recent progress of CDK4/6 inhibitors’ current practice in breast cancer
MYC induces CDK4/6 inhibitors resistance by promoting pRB1 degradation
CDK4/6 inhibitor palbociclib suppresses IgE-mediated mast cell activation
Recent advances of highly selective CDK4/6 inhibitors in breast cancer
Identification of potential novel drivers and biomarkers of CDK4/6 inhibitor resistance in metastatic breast cancer